Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Rising Doses of Faldaprevir in Healthy Japanese Males
NCT02182297Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules, Modified Peptides
01
Overview
Phase 1, randomised, double-blind trial in hepatitis C (HCV) comparing BI 201335 NA with Placebo (2 arms). Primary endpoints: Number of patients with abnormal findings in physical examination at Day 12, Number of patients with clinically significant changes in vital signs at Day 12 and 4 more. Started Apr 2008; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02182297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182297.